🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For readers interested in cancer immunotherapy, this review in the August issue discusses how delivery technologies such as lipid nanoparticles, hydrogels and scaffolds can reduce the clinical barriers for in situ cancer vaccines bit.ly/3Akxdks rdcu.be/dP17H

Comprehensive measurement of biopharmaceutical R&D investment bit.ly/4d8LY8A This new article analyses global R&D investment in 2021 for the full range of companies in the biopharma ecosystem, providing an estimate of ~$276 billion, larger than previous estimates

For readers interested in therapeutic strategies for cancer, this review in the August issue discusses the roles of reactive oxygen species (ROS) in cancer and the development of effective ROS-based cancer therapy bit.ly/3zCgglm rdcu.be/dQnC0

The breast cancer drug market tinyurl.com/3nbu6jev Major-market sales of breast cancer drugs totalled ~$28 billion in 2023, driven by CDK4/6 inhibitors and HER2-targeting agents. Find out more about leading products and emerging therapies in this new analysis

A golden age of muscarinic acetylcholine receptor modulation in neurological diseases tinyurl.com/mwpahd99 This new review covers advances in areas such as structure-based drug design supporting the development of M1 and M4 modulators for schizophrenia and Alzheimer disease

The muscarinic receptor agonist KarXT is on the cusp of FDA approval, potentially offering the first new mechanism of action for a schizophrenia therapy in more than 70 years. Read about this advance and the pipeline of muscarinic drugs in this news story tinyurl.com/3c6umar5

This Perspective by Terry Kenakin in the August issue discusses key factors in the assessments of the pharmacology of hit and lead compounds in the context of G-protein-coupled receptors as a target class tinyurl.com/bdfdp35y rdcu.be/dQ8lN

The FDA approved Servier’s IDH1 and IDH2 inhibitor vorasidenib for IDH-mutant glioma following surgery, providing the first new drug in decades for this rare cancer nature.com/articles/d4157…

This Nature Reviews Drug Discovery article from Andrew Tobin highlights drug discovery advances including those made at the WCNDD. 🔬 💊 🧬 Check it out! Lindsley Lab @ VU #schizophrenia #neuroscience #drugdiscovery #translationalresearch nature.com/articles/s4157…

Our latest research highlight covers a paper in Nature on DNA-sensing inflammasomes that cause recurrent atherosclerotic stroke, which potentially could be targeted by treatment with DNase nature.com/articles/d4157…

For readers interested in inflammasome signalling as a therapeutic target, here's a comprehensive review nature.com/articles/s4157… rdcu.be/dRHBe

This article in the August issue analyses design characteristics of the clinical pipeline of antibody-drug conjugates nature.com/articles/d4157…

For readers interested in antibody-drug conjugates as cancer therapies, here's a comprehensive review nature.com/articles/s4157… rdcu.be/dROhz

Neurocrine Biosciences said the lowest dose of an experimental pill for schizophrenia reduced psychosis reported by patients in a mid-stage study. trib.al/Mtz00p3

For readers interested in muscarinic receptor modulators for schizophrenia such as Neurocrine's NBI-‘568, here's a news story nature.com/articles/d4157… and a review nature.com/articles/s4157…

Join the virtual, two-day 𝐼𝑛 𝑠𝑖𝑙𝑖𝑐𝑜 #DrugDiscovery Workshop with top experts in the field. Learn cutting-edge techniques, network with professionals & enhance your skills for free! Register today: ncats.corsizio.com/event/6628253b… #AI #MachineLearning

Results from Alnylam’s heart drug study are a "grand slam." But competition looms from another treatment nearing potential approval. trib.al/X792pU9

For readers interested in siRNA therapeutics such as Alnylam's vutrisiran, here's a comprehensive recent review nature.com/articles/s4157… rdcu.be/dSJjN

Our September issue is live! Read about muscarinic receptor modulators for schizophrenia, chromatin remodellers as therapeutic targets, lipid nanoparticles for nucleic acid delivery, new epilepsy therapies in development and more here nature.com/nrd/volumes/23…

Protein isoform-centric therapeutics: expanding targets and increasing specificity tinyurl.com/2v5c3us8 Many genes encode multiple protein isoforms. This new review discusses targeting isoforms as a route to drugs with greater specificity and fewer adverse effects